This site is intended for healthcare professionals

Amryt announces FDA acceptance of NDA for Oleogel-S10 for the treatment of epidermolysis bullosa.

Read time: 1 mins
Last updated:28th Jun 2021
Published:3rd Jun 2021
Amryt announces that the FDA has accepted for filing Amryt’s New Drug Application (“NDA”) for Oleogel-S10 for the treatment of Epidermolysis Bullosa (“EB”).
Condition: Epidermolysis Bullosa
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest